Loading
The validation of a three-gene urine vesicle test that predicted high-grade prostate cancer at first biopsy better than standard clinical factors alone.
In independent validation in 519 patients, the urine exosome assay plus standard of care had an area under the curve of 0.73 (95% CI 0.68 to 0.77) against 0.63 for standard of care alone; 138 of 519 biopsies (27 per cent) would have been avoided, missing 5 per cent of patients with dominant pattern 4 high-risk Gleason 7 disease.
A urine RNA test can help some men skip a first prostate biopsy.
Shares ExoDx Prostate (IntelliScore), Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Prostate cancer.
Shares PSA and MRI-first prostate cancer screening, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares ExoDx Prostate (IntelliScore), PSA and MRI-first prostate cancer screening, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Prostate cancer.
Shares ExoDx Prostate (IntelliScore), Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Prostate cancer.
Shares ExoDx Prostate (IntelliScore), PSA and MRI-first prostate cancer screening, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/